Dr. Goodman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 W Gore St
Suite 407
Orlando, FL 32806Phone+1 407-210-1320Fax+1 321-202-2582- Is this information wrong?
Summary
- Ira Goodman, MD, is a board-certified neurologist specializing in Alzheimer’s disease, Parkinson’s disease, and memory disorders. The current Chief Medical Officer at SiteRx, Dr. Goodman previously ran a successful practice in Orlando, Florida and has been a Principal Investigator in 100+ clinical trials. Dr. Goodman is a 1979 graduate of the Medical College of Pennsylvania. He completed his internship in internal medicine at Orlando Regional Medical Center and his residency in Neurology at Shands Teaching Hospital at the University of Florida.
Education & Training
University of FloridaResidency, Neurology, 1980 - 1983
MCP-Hahnemann College of MedicineClass of 1979
Certifications & Licensure
FL State Medical License 1982 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI) Start of enrollment: 2013 Mar 01
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology Start of enrollment: 2013 Jun 01
- A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes Start of enrollment: 2017 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsEffect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.Peter A. Ljubenkov, Lauren Edwards, Leonardo Iaccarino, Renaud La Joie, Julio C. Rojas, Mary Koestler, Baruch Harris, Bradley F. Boeve, Barbara Borroni, John C. van Sw...> ;JAMA Network Open. 2021 Sep 1
- 107 citationsRandomized phase I clinical trial of anti-α-synuclein antibody BIIB054.Miroslaw Brys, Laura Fanning, Serena Hung, Aaron Ellenbogen, Natalia Penner, Minhua Yang, Mackenzie Welch, Erica Koenig, Eric David, Tara Fox, Shavy Makh, Jason Aldred...> ;Movement Disorders. 2019 Aug 1
- 181 citationsSafety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...Joseph Jankovic, Ira J. Goodman, Beth Safirstein, Tonya K. Marmon, Dale Schenk, Martin Koller, Wagner Zago, Daniel Ness, Sue G. Griffith, Michael Grundman, Jay Soto, S...> ;JAMA Neurology. 2018 Oct 1
- Join now to see all
Press Mentions
PUMPING IRONY: A Numbers GameJuly 30th, 2018
New Alzheimer’s Trials Show That Finding Patients for Treatments Is Becoming Insurmountable ObstacleJuly 24th, 2018
REM Sleep Disorder Can Make Sleepers Act Out Violent DreamsJuly 15th, 2017- Join now to see all
Hospital Affiliations
AdventHealth OrlandoOrlando, Florida
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
